Bullish Case: ACLS near $110 with 34% call-dominated volume and Helium's +3.13% signal; the Helium density shows a fat right shoulder toward $120-130, and AI/DRAM-driven implant demand plus oversold mean reversion (price action is mean reverting) could drive a snap toward $120-130 if Q3 earnings stabilize guidance. IV near 70-78% at ATM is elevated, so any clean beat collapses IV and lifts shares.

Bearish Case: Backwardated term structure, deep-OTM put IVs above 120-150%, and Helium's density mode at $105 below spot signal idiosyncratic downside. The historical return surface carries heavy negative-return mass, China/regulatory and merger overhang persists, and my prior upside calls (Feb +15-35%, Apr +6-12%) never materialized—de-rating risk toward $95-105 remains live.

Potential Outcomes:

1. Chop $105-120 (40%): IV bleeds into Nov 20 expiry; falsify if spot holds >120 with rising ATM call IV.
2. Relief to $125-140 (20%): beat/guidance, call-driven; falsify on failed break of $120.
3. Drift to $95-105 (25%): soft orders; falsify if 95P IV collapses.
4. Shock <$95 (15%): China/regulatory or macro risk-off; put skew steepens further.

October 27, 2026